Orphan & Fast Track
The number of targeted medicines and products serving rare and neglected diseases has grown and continues to rise. Regulatory pathways such as Orphan, Fast Track, or Breakthrough designations offer alternative pathways to market. While these smaller markets do not require large volumes, they do still require the skill, experience, and quality making finding the right CDMO important. Additionally, these projects require a personalized approach and should operate on a scale that is attractive to all parties to inspire a collaborative partnership.